Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma | MicrobiomeTrials← Back to trialsNCT07555470
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-04-10Est. Completion: 2029-12-31
Enrollment target: 80 participants Locations- Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
- Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, China
Other microbiome trials you might be interested in
Relapsed/Refractory Follicular LymphomaMarginal Zone Lymphoma
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab…
Fresno, United StatesEst. completion Jul 2028
Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Waldenström Macroglobulinemia (WM)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and c…
Multiple LocationsEst. completion Jun 30, 2029
Diffuse Large B Cell Lymphoma (DLBCL)Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)High-Grade B-Cell Lymphoma, NosPMBCLFollicular Grade 3 Lymphoma
Axatilimab + CAR-T in High-Risk Lymphoma
Atlanta, United StatesEst. completion Dec 31, 2028